ANDA 206585, held by Pharmobedient. Deferasirox.
As of Nov 15, 2026, ANDA 206585 (Deferasirox), held by Pharmobedient, was first approved by FDA on May 17, 2024, with 0 approved supplements and 0 published complete response letters.
| Date | Submission | Status | Documents |
|---|---|---|---|
| May 17, 2024 | Original application | Approved | None posted |
| Deferasirox125MG · tablet, for suspension;oral | Deferasirox | Discontinued |
| Deferasirox250MG · tablet, for suspension;oral | Deferasirox | Discontinued |
| Deferasirox500MG · tablet, for suspension;oral | Deferasirox | Discontinued |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. Drugs@FDA and FDA complete response letters
